The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) — HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing…


Previous articlePT296 – Dr. David Luke – Vital Psychedelic Conversations
Next articlePsychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?